Metastatic Breast Cancer
Metastatic Breast Cancer occurs when breast cancer cells spread beyond the breast to other parts of the body, such as bones, liver, or lungs, often leading to more severe symptoms and requiring advanced treatment.
Long-Term Safety Study of Ongoing Treatment with Study Drugs
We are providing continued access to a study drug for patients who are benefiting from it. The goal is to monitor its long-term safety as they continue treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer is a type of lung cancer that has spread to other parts of the body, often causing symptoms like persistent cough, chest pain, and difficulty breathing.
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer is a type of breast cancer characterized by the overexpression of the HER2 protein, which can lead to more aggressive tumor growth and requires targeted therapies.
Colorectal Cancer
Colorectal Cancer refers to cancer that starts in the colon or rectum, often presenting symptoms like changes in bowel habits, blood in stool, and abdominal discomfort.
HER2 Positive Gastric Cancer
HER2 Positive Gastric Cancer is a type of stomach cancer that shows overexpression of the HER2 protein, which can lead to more aggressive disease and requires specific treatment approaches.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you currently enrolled in a study sponsored by DS or DS/AZ?
- Do you have any ongoing health issues that would prevent you from participating in a study?
- Are you a female of childbearing potential and have you had a negative urine pregnancy test in the last month?
- Are you currently taking any medications that would prevent you from participating in this study?
- Have you been off T-DXd therapy for more than 18 weeks?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ds-8201a
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Grand Hopital De Charleroi
Medical Oncology
Charleroi, Belgium
Institut Gustave Roussy
Medical Oncology
Villejuif, France
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Oncologia Clinica Sperimentale di Senologia
Soccavo, Italy
Sponsor: Daiichi Sankyo Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.